PresseBox
Pressemitteilung BoxID: 590291 (Evotec AG)
  • Evotec AG
  • Manfred Eigen Campus, Essener Bogen 7
  • 22419 Hamburg
  • http://www.evotec.com
  • Ansprechpartner
  • Werner Lanthaler
  • +49 (40) 56081-242

Evotec extends drug discovery alliance with Genentech

(PresseBox) (Hamburg, ) Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for three additional years.

The collaboration was initiated in May 2010 and this extension further validates Evotec's technology platform and broad expertise in drug discovery.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are delighted and proud that Genentech has decided to extend the current agreement. Both sets of scientists have collaborated very closely over the past few years and this extension is validation of the value we bring to Genentech's discovery programmes.'

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.